key topics
navigation
|
Rethinking Fibromyalgia In Light Of Emerging Research
| | |
Few topics in rheumatology have generated as much controversy over the last 50 years as fibromyalgia. It is a very common symptom complex of wide variation and reportedly affects up to five percent of the female population. It is characterized mainly by widespread, often “total body” pain. In addition to pain that defies explanation by usual testing methods, patients also suffer from an extensive variety of symptoms that may include but are not limited to daytime fatigue, weight gain, depression, blurred vision, irritable bowel syndrome, severe sleep disruption, dizziness and multiple chemical sensitivities.
Patients are commonly sent to rheumatologists due to arthralgia (joint pain) because a primary care doctor becomes concerned about the development of inflammatory arthritis, lupus or some other autoimmune illness. Until about 20 years ago, many rheumatologists and primary care doctors believed that fibromyalgia was not an illness at all, that it had no basis in physiology and was, in fact, mostly “psychiatric.”
In fact, patients with fibromyalgia were often accused of being lazy, mentally ill or even malingerers trying to find an easy escape from life’s demands. Compounding the cases were a virtually complete lack of objective findings, normal lab results, normal X-rays, and a long list of seemingly unrelated and non-anatomical, and even bizarre sounding complaints that were far out of proportion to objective findings.
However, other rheumatologists believed that the syndrome represented a real malfunction of one or more organ systems. It was their opinion that it would have to be an impossible coincidence for five percent of females to come up with the same set of complaints even if the illness was psychological or psychiatric.
It is clear from even a cursory look that there is a huge variety of symptoms with fibromyalgia and they seemingly involve nearly every organ system in the body. However, if this is a real illness, how could all of the lab tests, X-rays and the physical examination be unrevealing?
If there is a real physiologic malfunction, it has to be in a system that makes contact with all parts of the body. Indeed, in recent years, fibromyalgia research suggests the brain is the location of the abnormalities that may cause the large variety of fibromyalgia symptoms. As we know, the brain has control centers for every organ system and is connected by nerves to every part of the body. Accordingly, it makes sense that a syndrome with such a huge diversity of symptoms could arise from brain and/or nervous system malfunctions. This would also explain why the usual diagnostic tests and X-rays that doctors perform are normal.
However, researchers have been able to use a special kind of MRI, a functional MRI, which actually can detect what areas of the brain are activated from a given stimulus and the given strength of that activation. Using this functional MRI and other advanced research methods, researchers have shown that the brains of those with fibromyalgia respond very differently to pain stimuli than the brains of people without fibromyalgia. In addition, sleep patterns in patients with fibromyalgia are clearly abnormal and this accounts, in part, for the severe sleep patterns suffered by most patients with fibromyalgia.
Accordingly, there is now a large body of widely accepted scientific data that reveal chemical, electrical and functional differences in the way that the brains of those with fibromyalgia handle various inputs and outputs in comparison to normal controls. Due to these recent advances in brain research and the preponderance of evidence for brain malfunction, fibromyalgia is no longer considered imaginary or purely psychological.
Sadly, treatment for the fibromyalgia syndrome is usually unsatisfactory. The challenge of the future is to figure out the exact nature of the malfunctions, why these malfunctions occur and how to treat them. Presently, none of these are very clear.
While there are literally hundreds of claims for successful treatment of fibromyalgia and thousands of Web sites on the subject, there is still no consensus on what treatments, if any, are universally successful. It is likely that no single treatment will be universally successful since all brains are “wired” differently. This adds to the frustration of doctors and patients who must deal with this illness daily. It is common knowledge that a treatment that is effective for one patient’s fibromyalgia may not be effective in other patients. Accordingly, treatment for fibromyalgia must be tailored to fit each individual patient. |
|
| Arthritis Practitioner - ISSN: 1 - Volume 3 - Issue 4 - July 2007 - Pages: - 42 | |
|
A complimentary CME Webcast Event
To register for this Web Archive program, click on Complimentary CME Webcast Event
This activity is for nurse practitioners, physician assistants, rheumatologists and internal medicine
physicians who treat patients with rheumatoid arthritis (RA).
Panelists/Lectures
"What You Should Know About Treating Early RA"
Nathan Wei, MD
Clinical Director
Arthritis and
Osteoporosis Center
Frederick, Md.
"A Closer Look At The Efficacy And Safety Of Combination Therapy With Anti-TNF Agents"
Philip Mease, MD
Clinical Professor
University of Washington
School of Medicine
Chief, Rheumatology Clinical Research
Swedish Hospital Medical Center
Seattle
"What The Studies Reveal About Emerging Therapies For RA"
Salahuddin Kazi, MD
Chief of Rheumatology
Presbyterian Hospital
Dallas,Tx.
This activity is supported by an educational grant from Genentech and Biogen Idec. The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).
A complimentary CME Webcast Event
ON DEMAND
(Q&A with panelists to follow lectures)
To register for this Webcast program, click on Complimentary CME Webcast
This activity is geared to physicians, rheumatologists, nurses, physician assistants and nurse practitioners who treat rheumatoid arthritis.
Agenda And Faculty
“Treating RA: The Shift To A More Aggressive Therapeutic Approach”
Linda Davis, MHS, PA-C
Assistant Professor
University Of North Texas Health Science Center
“What The Literature Reveals About Combination Therapy”
Kevin M. Latinis, MD, PhD
Division of Allergy, Clinical Immunology and Rheumatology
University of Kansas Medical Center
“New Biologic DMARDs: Can They Have An Impact?”
Salahuddin Kazi, MD
Chief of Rheumatology
Presbyterian Hospital
Dallas, Texas
This activity is supported by an educational grant from Bristol-Myers Squibb. The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).
A complimentary CME Web Archive Event
To register for this Web Archive program, click on Complimentary CME Web Archive Event
This activity is geared to physicians, nurses, physician assistants and nurse practitioners who treat osteoarthritis.
Agenda And Faculty
“A Closer Look At The Role Of Intraarticular Injections”
Frank Caruso, PA-C
Physician Assistant
Wake Forest University Baptist Medical Center
Winston-Salem, NC
“What The Literature Reveals About Viscosupplementation”
Nathan Wei, MD
Clinical Director
Arthritis and Osteoporosis Center
Frederick, MD
“Mastering The Technique Of Intraarticular Injections”
Mike Rudzinski, PA-C
Physician Assistant
Buffalo Veterans Affairs Medical Center
Buffalo, NY
This activity is supported by an educational grant from Genzyme. The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).
A Complimentary CME Webcast Event
A Complimentary, On-Demand CME Webcast
To register for this Webcast program, click on Complimentary CME Webcast Event
This activity is geared to physicians, nurses, physician assistants and nurse practitioners who treat rheumatoid arthritis.
AGENDA and FACULTY
"Reviewing The Role of DMARDs In Treating RA"
Don Flinn, PA-C
Physician Assistant, McBride Clinic, Oklahoma City, Ok.
Vice-President, Society Of Physician Assistants In Rheumatology
"Assessing The Potential of Biologic Therapies"
Mark Genovese, MD
Associate Professor of Medicine
Division of Immunology And Rheumatology
Stanford University School Of Medicine
"What You Should Know About Infusion Therapy"
Nathan Wei, MD
Clinical Director
Arthritis and Osteoporosis Center
Frederick, Md.
This activity is supported by an educational grant from Bristol-Myers Squibb.
The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).
|